Study estimates R&D spending on bringing new cancer drug to market

September 11, 2017, The JAMA Network Journals

Research and development costs are a common justification for high cancer drug prices and a new study published by JAMA Internal Medicine offers an updated estimate of the spending needed to bring a drug to the U.S. market.

Sham Mailankody, M.B.B.S., of the Memorial Sloan Kettering Cancer Center, New York, and coauthors analyzed U.S. Securities and Exchange Commission filings for drug companies with no drugs on the U.S. market that received approval from the U.S. Food and Drug Administration for a cancer drug from 2006 through 2015. The analysis by the authors included 10 companies and drugs. They used a different approach to update previous estimates that had ranged from $320 million to $2.7 billion to develop one new drug.

The authors report:

  • The 10 companies had a median time of 7.3 years to develop a drug.
  • The median cost of drug development was $648 million.
  • The total revenue of these 10 drugs was $67 billion from the time of approval to December 2016 or until the company sold or licensed the compound to another company.
  • The median revenue for these companies in 2017 U.S. dollars was about $1.6 billion and the average was almost $6.7 billion.

The authors acknowledge study limitations, including a small data set. The analysis also pertains only to cancer drugs and cannot be extrapolated to other sectors where drug development can be harder for biological reasons.

"This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing," the article concludes.

Explore further: FDA recalls heart medication valsartan, citing cancer concerns

More information: JAMA Internal Medicine (2017). doi:10.1001/jamainternmed.2017.3601

Related Stories

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

Chinese firm recalls heart drug as US, EU raise concerns

July 18, 2018
The Chinese manufacturer of a widely used blood pressure medication said it had launched a global recall after US and European regulators warned of contamination by a cancer-causing impurity.

Life-extending immunotherapy approved on NHS for children with neuroblastoma

July 16, 2018
Children in England with high-risk neuroblastoma will now be offered a cancer drug that could extend their life.

Canadian court rebuffs tobacco firm in major damages suit

July 13, 2018
US cigarette maker Philip Morris suffered a setback Friday in a long-running suit when Canada's Supreme Court denied it access to personal data on people suffering from tobacco-related diseases.

'Embattled' breast cancer drugs could be revived by new discovery

June 25, 2018
More than 60 percent of breast cancer cases involve defects in the same biochemical chain of events within cancer cells—known as the PI3 kinase (PI3K) pathway—but efforts to develop therapies targeting this pathway have ...

Research team discovers drug compound that stops cancer cells from spreading

June 22, 2018
Fighting cancer means killing cancer cells. However, oncologists know that it's also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature ...

Recommended for you

Novel botulinum toxin compound relieves chronic pain

July 18, 2018
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to research by UCL, ...

Opioids given too easily to children: study

July 16, 2018
(HealthDay)—Many children are prescribed powerful opioid painkillers they don't really need, putting them and those around them at risk, a new study shows.

Study reveals opioid patients face multiple barriers to treatment

July 12, 2018
In areas of the country disproportionately affected by the opioid crisis, treatment programs are less likely to accept patients paying through insurance of any type or accept pregnant women, a new Vanderbilt study found.

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.

Study finds no strong evidence that cannabis reduces chronic pain

July 4, 2018
A four-year study suggests medicinal cannabis is not as effective at relieving chronic non-cancer pain as commonly assumed.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.